Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(2.02)
# 2,969
Out of 4,944 analysts
117
Total ratings
39.81%
Success rate
-8.45%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Maintains: Buy | $10 → $12 | $0.57 | +1,987.68% | 5 | Aug 5, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Buy | $48 → $56 | $36.33 | +54.14% | 7 | Aug 1, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $10 → $12 | $5.22 | +129.89% | 6 | Jul 18, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.11 | +620.72% | 4 | Jun 27, 2025 | |
| ARDX Ardelyx | Assumes: Buy | $10 | $5.60 | +78.57% | 1 | Jun 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $13.51 | +210.88% | 9 | Jun 17, 2025 | |
| LYRA Lyra Therapeutics | Maintains: Neutral | $2 → $16 | $6.75 | +137.04% | 8 | Jun 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $20 | $10.38 | +92.68% | 10 | Jun 9, 2025 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $8 | $3.32 | +140.96% | 1 | Jun 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Assumes: Buy | $72 | $51.36 | +40.19% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.36 | +86.57% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $15.90 | +88.68% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.47 | +1,114.57% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $10.61 | +201.60% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.85 | +1,073.43% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $2.06 | -2.91% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $8.52 | -64.79% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $6.15 | +485.37% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $348.33 | -91.96% | 1 | Aug 22, 2023 |
FibroBiologics
Aug 5, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $0.57
Upside: +1,987.68%
LENZ Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $36.33
Upside: +54.14%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $5.22
Upside: +129.89%
Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.11
Upside: +620.72%
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.60
Upside: +78.57%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $13.51
Upside: +210.88%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2 → $16
Current: $6.75
Upside: +137.04%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $10.38
Upside: +92.68%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.32
Upside: +140.96%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $51.36
Upside: +40.19%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.36
Upside: +86.57%
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $15.90
Upside: +88.68%
May 15, 2025
Reiterates: Buy
Price Target: $30
Current: $2.47
Upside: +1,114.57%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $10.61
Upside: +201.60%
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $0.85
Upside: +1,073.43%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $2.06
Upside: -2.91%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $8.52
Upside: -64.79%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $6.15
Upside: +485.37%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $348.33
Upside: -91.96%